Shots:
- The first study highlights the results from the analytical assessment of the safety & efficacy of SB17 vs Stelara (ustekinumab) which demonstrated SB17 to be biologically similar to Stelara in terms of its physicochemical, structural & biological attributes
- Additionally, the data supports the similarity of SB17 with reference Stelara in terms of the biosimilarity, PK, PD & clinical effect in patients suffering from moderate-to-severe psoriasis
- Samsung Bioepis has recently signed a collaborative agreement with Sandoz to commercialize SB17 across the US, EU, UK, Canada & Switzerland
Ref: Samsung Bioepis | Image: Samsung Bioepis | Press Release
Related News:- Celltrion Presents the Long-Term Data for CT-P13 (biosimilar, infliximab) to Treat Inflammatory Bowel Disease (IBD) at ECCO 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
